ArticleCellular and molecular gastroenterology and hepatology2026
Intervening in p53-Induced Death Domain Protein 1 to Decrease Regulatory T Cell Recruitment Boosts the Effectiveness of Radiofrequency Ablation Combined With Anti-Programmed Cell Death Protein-1 Therapy in Hepatocellular Carcinoma.
Article in Cellular and molecular gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsThe efficacy of radiofrequency ablation is constrained by incomplete tumor ablation, particularly in cases of excessive tumor volume, leading to elevated recurrence rates. Elucidating the genetic and microenvironmental alterations following incomplete ablation is essential for improving therapeutic outcomes. We aimed to identify the tumor-intrinsic molecular link between residual tumor cells and the immunosuppressive microenvironment that drives recurrence after radiofrequency ablation.
methodsWe retrospectively compared recurrence in hepatocellular carcinoma patients treated with radiofrequency ablation or liver resection and established complete and incomplete radiofrequency ablation mouse models. Transcriptomic dataset analysis (differentially expressed genes and weighted gene coexpression network analysis) combined with single-cell RNA sequencing was used to identify candidate genes linking incomplete ablation to regulatory T cell recruitment. Mechanistic roles were validated by Western blotting, reverse transcription quantitative polymerase chain reaction, flow cytometry, enzyme-linked immunosorbent assay, immunohistochemistry/immunofluorescence, and T-cell coculture assays, and the effect of p53-induced death domain protein 1 knockdown combined with anti-programmed cell death protein-1 therapy was assessed in vivo.
resultsAnalysis of tumor recurrence post radiofrequency ablation revealed a significantly higher local recurrence rate in primary tumors exceeding 2 cm in size, indicating that incomplete ablation is a critical driver of local tumor regrowth. In preclinical animal models, incomplete radiofrequency ablation was associated with increased infiltration of regulatory T cells. Gene expression profiling identified marked upregulation of p53-induced death domain protein 1, which strongly correlated with regulatory T cell infiltration and unfavorable prognosis. Mechanistic studies demonstrated that p53-induced death domain protein 1 enhanced p53 expression via the caspase-2/murine double minute 2 axis, promoted transforming growth factor-β1 secretion, and drove T-cell differentiation into regulatory T cells. Silencing p53-induced death domain protein 1 in hepatocellular carcinoma cells reduced regulatory T cell infiltration and heightened sensitivity to immunotherapy. Strikingly, combining radiofrequency ablation with immunotherapy following p53-induced death domain protein 1 knockdown significantly enhanced treatment efficacy.
conclusionsThese findings provide a robust theoretical and practical basis for integrating radiofrequency ablation with anti-programmed cell death protein-1-targeted therapy to mitigate recurrence and optimize clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.